Skip to content

Released Aug 7, 2025, before the open

10-Q filed Aug 7, 2025, 38 days after period end · 0001628280-25-038619

Q2 2025 · 10-Q
Revenue$1.12M— vs Q2 2024−23.3% vs Q1 2025
Net Income-$52.59MN/M vs Q2 2024N/M vs Q1 2025
EPS Diluted-$0.41N/M vs Q2 2024N/M vs Q1 2025
Operating Income-$53,377,000N/M
Operating Cash Flowderived-$41,412,000N/M
Free Cash Flowderived-$42,984,000N/M
Margins · derived
Operating margin-4787.2%
Net margin-4716.7%

What the release said

The release

Same quarter

MetricQ2 2025Q2 2024Q2 2023Q2 2022
Revenue$1.12M$0.00$0.00—
Net Income-$52.59M-$55.33M-$42.39M-$29.35M
EPS Diluted-$0.41-$0.46-$0.47-$1.76

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR